IRF2
Interferon regulatory factor 2
Also known as: IRF2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P14316
- Gene
- IRF2
- Ensembl
- ENSG00000168310
- Chromosome
- 4
- Canonical length
- 349 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Cell Junctions,Cytosol
OverviewNCBI Gene
IRF2 encodes interferon regulatory factor 2, a member of the interferon regulatory transcription factor (IRF) family. IRF2 competitively inhibits the IRF1-mediated transcriptional activation of interferons alpha and beta, and presumably other genes that employ IRF1 for transcription activation. However, IRF2 also functions as a transcriptional activator of histone H4. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
349 residues, UniProt reviewed canonical sequence.
>P14316|IRF2
1 MPVERMRMRP WLEEQINSNT IPGLKWLNKE KKIFQIPWMH AARHGWDVEK DAPLFRNWAI
61 HTGKHQPGVD KPDPKTWKAN FRCAMNSLPD IEEVKDKSIK KGNNAFRVYR MLPLSERPSK
121 KGKKPKTEKE DKVKHIKQEP VESSLGLSNG VSDLSPEYAV LTSTIKNEVD STVNIIVVGQ
181 SHLDSNIENQ EIVTNPPDIC QVVEVTTESD EQPVSMSELY PLQISPVSSY AESETTDSVP
241 SDEESAEGRP HWRKRNIEGK QYLSNMGTRG SYLLPGMASF VTSNKPDLQV TIKEESNPVP
301 YNSSWPPFQD LPLSSSMTPA SSSSRPDRET RASVIKKTSD ITQARVKSCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IRF2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.61
- Highest tissue expression
- 52 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 52 nTPM
- tonsil: 45 nTPM
- spleen: 45 nTPM
- thymus: 43 nTPM
- appendix: 42 nTPM
- liver: 32 nTPM
Single-cell type
- neutrophils: 378 nCPM
- kupffer cells: 199 nCPM
- ocular epithelial cells: 181 nCPM
- plasma cells: 144 nCPM
- cardiomyocytes: 142 nCPM
- platelets: 138 nCPM
Immune cell
- neutrophil: 357 nTPM
- eosinophil: 159 nTPM
- non-classical monocyte: 130 nTPM
- intermediate monocyte: 109 nTPM
- T-reg: 101 nTPM
- naive B-cell: 98 nTPM
Brain region
- medulla oblongata: 28 nTPM
- white matter: 28 nTPM
- pons: 26 nTPM
- cerebellum: 26 nTPM
- basal ganglia: 26 nTPM
- hypothalamus: 26 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.8
- gnomAD missense Z
- 2.31
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell population proliferation
- defense response to virus
- immune system process
- negative regulation of transcription by RNA polymerase II
- negative regulation of type I interferon production
- positive regulation of transcription by RNA polymerase II
- regulation of DNA-templated transcription
- regulation of transcription by RNA polymerase II
- toll-like receptor 3 signaling pathway
Molecular functions
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IRF2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IRF2 as an antibody target. Whether an autoantibody or antibody against IRF2 could matter depends on whether native IRF2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IRF2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IRF2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...